Editas Medicine Inc [EDIT] stock prices are down -3.89% to $2.72 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The EDIT shares have gain 6.25% over the last week, with a monthly amount drifted -0.37%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Editas Medicine Inc [NASDAQ: EDIT] stock has seen the most recent analyst activity on April 28, 2025, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $3. Previously, JP Morgan downgraded its rating to Underweight on December 16, 2024. On December 13, 2024, downgrade downgraded it’s rating to Hold. Stifel downgraded its rating to a Hold and decreased its price target to $3 on December 13, 2024. Chardan Capital Markets downgraded its rating to a Neutral. Wells Fargo downgraded its rating to Equal Weight for this stock on December 11, 2024, and downed its price target to $4. In a note dated November 25, 2024, BofA Securities downgraded an Underperform rating on this stock and revised its target price from $13 to $1.
The stock price of Editas Medicine Inc [EDIT] has been fluctuating between $0.91 and $4.12 over the past year. Currently, Wall Street analysts expect the stock to reach $12.85 within the next 12 months. Editas Medicine Inc [NASDAQ: EDIT] shares were valued at $2.72 at the most recent close of the market. An investor can expect a potential return of 372.43% based on the average EDIT price forecast.
Analyzing the EDIT fundamentals
The Editas Medicine Inc [NASDAQ:EDIT] reported sales of 38.90M for trailing twelve months, representing a surge of 597.47%. Gross Profit Margin for this corporation currently stands at 0.92% with Operating Profit Margin at -6.17%, Pretax Profit Margin comes in at -6.09%, and Net Profit Margin reading is -6.09%. To continue investigating profitability, this company’s Return on Assets is posted at -1.12, Equity is -2.42 and Total Capital is -1.66. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 4.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Editas Medicine Inc [NASDAQ:EDIT]’s Current Ratio is 2.77. Also, the Quick Ratio is 2.77, while the Cash Ratio stands at 2.1. Considering the valuation of this stock, the price to sales ratio is 6.29, the price to book ratio is 12.39.
Transactions by insiders
Recent insider trading involved Burkly Linda, EVP, CHIEF SCIENTIFIC OFFICER, that happened on Sep 03 ’25 when 710.0 shares were sold. SVP, Chief Financial Officer, Parison Amy completed a deal on Sep 03 ’25 to sell 458.0 shares. Meanwhile, CEO O’Neill Gilmore Neil sold 5592.0 shares on Sep 03 ’25.
